These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20548212)

  • 21. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Measles, mumps, rubella: important health risks].
    Rev Infirm; 2000 Oct; (64):13-5. PubMed ID: 11288443
    [No Abstract]   [Full Text] [Related]  

  • 23. Live virus immunization after orthotopic liver transplantation.
    Khan S; Erlichman J; Rand EB
    Pediatr Transplant; 2006 Feb; 10(1):78-82. PubMed ID: 16499592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommended childhood immunization schedule--United States, July-December 1996. Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the Food and Drug Administration (FDA).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Jul; 45(29):635-8. PubMed ID: 8965793
    [No Abstract]   [Full Text] [Related]  

  • 26. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 27. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
    Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
    Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Overview of measles, mumps, rubella and varicella vaccination in adolescents and adults].
    Quast U; Arndt U
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S77-81. PubMed ID: 19353476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Epidemiologic study of measles, rubella and mumps with regard to the possibility of their control by immunization].
    Rodríguez Borrego MJ; García León J; Bolumar F; Nájera E
    Rev Sanid Hig Publica (Madr); 1985; 59(1-2):117-25. PubMed ID: 4059834
    [No Abstract]   [Full Text] [Related]  

  • 30. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia.
    Wood JG; Gidding HF; Heywood A; Macartney K; McIntyre PB; Macintyre CR
    Vaccine; 2009 Jan; 27(2):313-8. PubMed ID: 18977272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Mar; 57(10):258-60. PubMed ID: 18340332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IAP guidelines on optional vaccines and related matters.
    John TJ
    Indian Pediatr; 1999 Jul; 36(7):677-9. PubMed ID: 10740304
    [No Abstract]   [Full Text] [Related]  

  • 33. Chickenpox: An update.
    Lo Presti C; Curti C; Montana M; Bornet C; Vanelle P
    Med Mal Infect; 2019 Feb; 49(1):1-8. PubMed ID: 29789159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factsheet: measles.
    N S W Public Health Bull; 2012 Dec; 23(9-10):209. PubMed ID: 23442999
    [No Abstract]   [Full Text] [Related]  

  • 35. Measles immunization in Saudi Arabia: the need for change.
    Khalil MK; Al-Mazrou YY; Al-Jeffri M; Al-Ghamdy YS
    East Mediterr Health J; 2001; 7(4-5):829-34. PubMed ID: 15332786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Measles Control Campaign and immunisation adverse events.
    Burgess MA; Heath TC; McIntyre PB
    Commun Dis Intell; 1998 Jul; 22(7):136-8. PubMed ID: 9684532
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catch-up immunization programs will eliminate measles threat for most schoolchildren.
    Rafuse J
    CMAJ; 1996 May; 154(10):1567-8. PubMed ID: 8625011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles vaccines and the potential for worldwide eradication of measles.
    Meissner HC; Strebel PM; Orenstein WA
    Pediatrics; 2004 Oct; 114(4):1065-9. PubMed ID: 15466106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moving the second dose of measles-mumps-rubella vaccine to school entry: implications for control of rubella.
    Heath TC; Burgess MA; Forrest JM
    Commun Dis Intell; 1998 Aug; 22(8):157-8. PubMed ID: 9735550
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.